SEC Form SC 13G/A filed by Yumanity Therapeutics Inc. (Amendment)
$YMTX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
SC 13G - KINETA, INC./DE (0001445283) (Subject)
SC 13D/A - KINETA, INC./DE (0001445283) (Subject)
SC 13G/A - KINETA, INC./DE (0001445283) (Subject)
HC Wainwright & Co. initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $39.00
Jefferies initiated coverage of Yumanity Therapeutics with a rating of Buy and set a new price target of $35.00
4 - KINETA, INC./DE (0001445283) (Issuer)
4 - KINETA, INC./DE (0001445283) (Issuer)
4 - KINETA, INC./DE (0001445283) (Issuer)
4 - KINETA, INC./DE (0001445283) (Issuer)
4 - KINETA, INC./DE (0001445283) (Issuer)
4 - KINETA, INC./DE (0001445283) (Issuer)
Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci
Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger, which are subject to stockholder approval BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"). The special dividend, which the Company estimates will be in range of $1.34 to $1.43 per share of Yumanity common stock, will be payable in cash on or before December 29, 20
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company's recent corporate developments. Recent Corporate Developments On November 10, 2022, Yumanity announced the effectiveness of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with Yumanity's previously announced proposed sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanit
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. ("Yumanity" or the "Company") (NASDAQ:YMTX) today announced that the registration statement on Form S-4 (the "Registration Statement"), relating to the previously announced asset sale to Janssen Pharmaceutica NV ("Janssen") and merger with Kineta, Inc. ("Kineta"), has been declared effective by the U.S. Securities and Exchange Commission. In June 2022, the Company announced definitive agreements for two strategic transactions. The first definitive agreement is an asset purchase agreement for the sale of Yumanity's lead clinical-stage product candidate, YTX-7739, as well as Yumanity's unpartnered discovery-stage neurosci
8-K - KINETA, INC./DE (0001445283) (Filer)
8-K - KINETA, INC./DE (0001445283) (Filer)
8-K - KINETA, INC./DE (0001445283) (Filer)
According to Benzinga Pro data, during Q3, Yumanity Therapeutics (NASDAQ:YMTX) posted sales of $1.40 million. Earnings were up 30.59%, but Yumanity Therapeutics still reported an overall loss of $3.36 million. In Q2, Yumanity Therapeutics brought in $1.66 million in sales but lost $4.84 million in earnings. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Yu
Gainers Exact Sciences (NASDAQ:EXAS) shares increased by 17.9% to $52.6 during Friday's pre-market session. The company's market cap stands at $9.3 billion. IMAC Holdings (NASDAQ:BACK) shares increased by 15.71% to $0.28. The company's market cap stands at $9.2 million. Adagene (NASDAQ:ADAG) shares moved upwards by 13.63% to $1.5. The market value of their outstanding shares is at $65.1 million. Monopar Therapeutics (NASDAQ:MNPR) shares moved upwards by 12.45% to $2.98. The market value of their outstanding shares is at $38.3 million. Rezolute (NASDAQ:RZLT) stock rose 10.73% to $1.65. The market value of their outstanding shares is at $60.7 million. Prenetics Global (NASDAQ:PRE) stock
BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Michael D. Wyzga as Senior Vice President, Chief Financial Officer. "Michael's financial expertise combined with his proven ability to execute strategic and operational objectives will be invaluable to the Company," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "We are looking forward to Michael's contributions as we continue to pursue our vision of a future f
BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Devin W. Smith as Senior Vice President and General Counsel. "We are delighted to welcome Devin as our general counsel at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "His experience providing legal counsel to public emerging life science companies will be important as we advance three clinical programs, move new innovative assets to t
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the appointment of Ajay Verma, M.D., Ph.D., as Executive Vice President, Head of Research & Development. Dr. Verma brings more than 25 years of experience developing biotherapeutics in the field of neuroscience. "We are delighted to welcome Dr. Ajay Verma in the newly-created role of Head of R&D at Yumanity Therapeutics," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity Therapeutics. "As a clinically trained neurologist, A